A Study to Evaluate the Safety and Tolerability of AZD7442 in Chinese Adults
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of a single dose of 600 mg AZD7442 administered IV
(intravenous) to Chinese adults (including those with stable medical conditions).